Table 2:
5AR inhibitor use and upper gastro-oesophageal cancer riskb
| Medication | Cases n,(%) | Controls n,(%) | Unadjusted OR (95% CI)c | Adjusted OR (95% CI)d | P-value |
|---|---|---|---|---|---|
|
| |||||
| Gastro-oesophageal | |||||
| Any 5AR inhibitor | |||||
| Never use | 1,949 (97.3) | 9,343 (96.8) | Ref | Ref | |
| Ever use | 54 (2.7) | 307 (3.2) | 0.80 (0.59,1.08) | 0.75 (0.56,1.02) | 0.065 |
| <365 DDDs | 22 (1.1%) | 127 (1.3%) | 0.77 (0.49,1.22) | 0.74 (0.47,1.17) | 0.201 |
| 366 – 1095 DDDs | 22 (1.1%) | 100 (1.0%) | 1.03 (0.64,1.65) | 0.94 (0.58,1.53) | 0.813 |
| >1095 DDDs | 10 (0.5%) | 80 (0.8%) | 0.57 (0.29,1.10) | 0.54 (0.27,1.05) | 0.071 |
| Finasteride | |||||
| Never use | 1,956 (97.7) | 9,357 (97.0) | Ref | Ref | |
| Ever use | 47 (2.3) | 293 (3.0) | 0.73 (0.53,1.00) | 0.68 (0.50,0.94) | 0.020 |
| <365 DDDs | 18 (0.9%) | 119 (1.2%) | 0.69 (0.42,1.13) | 0.65 (0.39,1.07) | 0.090 |
| 366 – 1095 DDDs | 20 (1.0%) | 95 (1.0%) | 0.98 (0.60,1.61) | 0.90 (0.54,1.48) | 0.667 |
| >1095 DDDs | 9 (0.4%) | 79 (0.8%) | 0.51 (0.25,1.03) | 0.49 (0.24,0.99) | 0.046 |
| Dutasteride | |||||
| Never use | 1,995 (99.6) | 9,627 (99.8) | Ref | Ref | |
| Ever use | 8 (0.4) | 23 (0.2) | 1.53 (0.67,3.48) | 1.53 (0.67,3.50) | 0.312 |
| <365 DDDs | 6 (0.3%) | 18 (0.2%) | 1.41 (0.55,3.61) | 1.45 (0.56,3.73) | 0.439 |
| 366 – 1095 DDDs | 1 (0.0%) | 4 (0.0%) | 1.21 (0.12,12.06) | 1.16 (0.12,11.65) | 0.899 |
| >1095 DDDs | 1 (0.0%) | 1 (0.0%) | 5.00 (0.31,79.94) | 4.03 (0.25,65.80) | 0.328 |
|
| |||||
| Oesophageal | |||||
| Any 5AR inhibitor | |||||
| Never use | 1,326 (97.2) | 6,366 (96.9) | Ref | Ref | |
| Ever use | 38 (2.8) | 202 (3.1) | 0.85 (0.59,1.21) | 0.78 (0.55,1.13) | 0.191 |
| <365 DDDs | 14 (1.0%) | 86 (1.3%) | 0.71 (0.40,1.26) | 0.67 (0.38,1.20) | 0.178 |
| 366 – 1095 DDDs | 15 (1.1%) | 64 (1.0%) | 1.09 (0.61,1.95) | 1.00 (0.55,1.80) | 0.990 |
| >1095 DDDs | 9 (0.7%) | 52 (0.8%) | 0.79 (0.38,1.63) | 0.72 (0.35,1.51) | 0.387 |
|
| |||||
| Gastric | |||||
| Any 5AR inhibitor | |||||
| Never use | 623 (97.5) | 2,977 (96.6) | Ref | Ref | |
| Ever use | 16 (2.5) | 105 (3.4) | 0.71 (0.42,1.21) | 0.68 (0.39,1.17) | 0.162 |
| <365 DDDs | 8 (1.3%) | 41 (1.3%) | 0.91 (0.43,1.95) | 0.86 (0.40,1.86) | 0.701 |
| 366 – 1095 DDDs | 7 (1.1%) | 36 (1.2%) | 0.93 (0.41,2.11) | 0.87 (0.38,2.00) | 0.745 |
| >1095 DDDs | 1 (0.2%) | 28 (0.9%) | 0.16 (0.02,1.18) | 0.16 (0.02,1.20) | 0.075 |
b
OR: odds ratio; CI: confidence interval
c
Conditioned on year of birth, general practice and year of diagnosis
d
Additionally adjusted for use of aspirin, statins and proton pump inhibitors, and the presence of myocardial infarction, heart failure, peripheral vascular disease, cerebrovascular disease, connective tissue disease, dementia, chronic obstructive pulmonary disease, rheumatoid arthritis, diabetes, renal disease and liver disease.